New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:08 EDTTXMDTherapeuticsMD receives enrollment approval for Phase 3 trial of TX 12-001HR
TherapeuticsMD announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
News For TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTTXMDStifel to hold a conference
Subscribe for More Information
November 13, 2014
09:45 EDTTXMDNYSE reports issue affecting one NYSE MKT workstation
The NYSE MKT cash equities market is currently experiencing an issue with one workstation affecting order processing and trade execution in nine symbols, it announced in a market status alert. The impacted symbols are Cornerstone Progressive Return Fund (CFP), Alpha Pro Tech (APT), Denison Mines (DNN), First Austrailian Prime Income Fund (FAX), iBio (IBIO), inTEST (INTT), Provectus (PVCT), TherapeuticsMD (TXMD) and Uranerz Energy (URZ). The NYSE MKT will issue a non-regulatory halt condition in the symbols and will not be trading these securities for the remainder of the day, it stated. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use